Sectors & IndustriesHealthcareDiagnostics & Research

Best Diagnostic & Research Stocks to Buy Now (2023)

Top diagnostic & research stocks in 2023 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

Star Equity Holdings (NASDAQ:STRR) is the top diagnostic & research stock with a Zen Score of 50, which is 23 points higher than the diagnostic & research industry average of 27. It passed 19 out of 38 due diligence checks and has strong fundamentals. Star Equity Holdings has seen its stock lose -0.93% over the past year.

Laboratory Of America Holdings (NYSE:LH) is the second best diagnostic & research stock with a Zen Score of 50, which is 23 points higher than the diagnostic & research industry average of 27. It passed 18 out of 38 due diligence checks and has strong fundamentals. Laboratory Of America Holdings has seen its stock lose -3.7% over the past year, underperforming other diagnostic & research stocks by -3 percentage points.

Laboratory Of America Holdings has an average 1 year price target of $245.63, an upside of 19.73% from Laboratory Of America Holdings's current stock price of $205.15.

Laboratory Of America Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Laboratory Of America Holdings, 62.5% have issued a Strong Buy rating, 25% have issued a Buy, 12.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Charles River Laboratories International (NYSE:CRL) is the third best diagnostic & research stock with a Zen Score of 44, which is 17 points higher than the diagnostic & research industry average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Charles River Laboratories International has seen its stock return 8% over the past year, overperforming other diagnostic & research stocks by 9 percentage points.

Charles River Laboratories International has an average 1 year price target of $237.10, an upside of 18.78% from Charles River Laboratories International's current stock price of $199.62.

Charles River Laboratories International stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Charles River Laboratories International, 40% have issued a Strong Buy rating, 20% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

Psychemedics (NASDAQ:PMD) has an annual dividend yield of 5.71%, which is 4 percentage points higher than the diagnostic & research industry average of 1.58%. Psychemedics's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Psychemedics's dividend has not shown consistent growth over the last 10 years.

Psychemedics's dividend payout ratio of -82.4% indicates that its high dividend yield might not be sustainable for the long-term.

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.22%, which is 1 percentage points higher than the diagnostic & research industry average of 1.58%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 39.1% indicates that its dividend yield is sustainable for the long-term.

Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.4%, which is the same as the diagnostic & research industry average of 1.58%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 30.6% indicates that its dividend yield is sustainable for the long-term.

Diagnostic & research stocks were up 0.07% in the last day, and down -4.81% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are up.

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 100, which is 76 points higher than the diagnostic & research industry average of 24. It passed 7 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has dropped -0.93% in the past year. It has performed in line with other stocks in the diagnostic & research industry.

Fonar (NASDAQ:FONR) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 47 points higher than the diagnostic & research industry average of 24. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 10.45% in the past year. It has overperformed other stocks in the diagnostic & research industry by 11 percentage points.

Laboratory Of America Holdings (NYSE:LH) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Laboratory Of America Holdings has a valuation score of 57, which is 33 points higher than the diagnostic & research industry average of 24. It passed 4 out of 7 valuation due diligence checks.

Laboratory Of America Holdings's stock has dropped -3.7% in the past year. It has underperformed other stocks in the diagnostic & research industry by -3 percentage points.